Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 45

References for PMC Articles for PubMed (Select 20029944)


Genetic variations in xenobiotic metabolic pathway genes, personal hair dye use, and risk of non-Hodgkin lymphoma.

Zhang Y, Hughes KJ, Zahm SH, Zhang Y, Holford TR, Dai L, Bai Y, Han X, Qin Q, Lan Q, Rothman N, Zhu Y, Leaderer B, Zheng T.

Am J Epidemiol. 2009 Nov 15;170(10):1222-30. doi: 10.1093/aje/kwp263. Epub 2009 Oct 12.


E. coli nitroreductase/CB1954 gene-directed enzyme prodrug therapy: role of arylamine N-acetlytransferase 2.

Mitchell DJ, Minchin RF.

Cancer Gene Ther. 2008 Nov;15(11):758-64. doi: 10.1038/cgt.2008.47. Epub 2008 Jul 4.


Implication of Xenobiotic Metabolizing Enzyme gene (CYP2E1, CYP2C19, CYP2D6, mEH and NAT2) polymorphisms in breast carcinoma.

Khedhaier A, Hassen E, Bouaouina N, Gabbouj S, Ahmed SB, Chouchane L.

BMC Cancer. 2008 Apr 18;8:109. doi: 10.1186/1471-2407-8-109.


Lymphoma survival patterns by WHO subtype in the United States, 1973-2003.

Han X, Kilfoy B, Zheng T, Holford TR, Zhu C, Zhu Y, Zhang Y.

Cancer Causes Control. 2008 Oct;19(8):841-58. doi: 10.1007/s10552-008-9147-4. Epub 2008 Mar 26.


Polymorphisms of drug-metabolizing enzymes CYP1A1, GSTT and GSTP contribute to the development of diffuse large B-cell lymphoma risk in the Saudi Arabian population.

Al-Dayel F, Al-Rasheed M, Ibrahim M, Bu R, Bavi P, Abubaker J, Al-Jomah N, Mohamed GH, Moorji A, Uddin S, Siraj AK, Al-Kuraya K.

Leuk Lymphoma. 2008 Jan;49(1):122-9. doi: 10.1080/10428190701704605.


Polymorphisms in xenobiotic-metabolizing genes and the risk of chronic lymphocytic leukemia and non-Hodgkin's lymphoma in adult Russian patients.

Gra OA, Glotov AS, Nikitin EA, Glotov OS, Kuznetsova VE, Chudinov AV, Sudarikov AB, Nasedkina TV.

Am J Hematol. 2008 Apr;83(4):279-87.


Polymorphisms in genes encoding drug metabolizing enzymes and their influence on the outcome of children with neuroblastoma.

Ashton LJ, Murray JE, Haber M, Marshall GM, Ashley DM, Norris MD.

Pharmacogenet Genomics. 2007 Sep;17(9):709-17.


NAT2 polymorphism in Omani gastric cancer patients-risk predisposition and clinicopathological associations.

Al-Moundhri MS, Al-Kindi M, Al-Nabhani M, Al-Bahrani B, Burney IA, Al-Madhani A, Ganguly SS, Tanira M.

World J Gastroenterol. 2007 May 21;13(19):2697-702.


Glutathione-S-transferase genotypes influence prognosis in follicular non-Hodgkin's Lymphoma.

Hohaus S, Mansueto G, Massini G, D'Alo F, Giachelia M, Martini M, Larocca LM, Voso MT, Leone G.

Leuk Lymphoma. 2007 Mar;48(3):564-9.


Endogenous glutathione adducts.

Blair IA.

Curr Drug Metab. 2006 Dec;7(8):853-72. Review.


Genetic polymorphisms in the oxidative stress pathway and susceptibility to non-Hodgkin lymphoma.

Lan Q, Zheng T, Shen M, Zhang Y, Wang SS, Zahm SH, Holford TR, Leaderer B, Boyle P, Chanock S.

Hum Genet. 2007 Apr;121(2):161-8. Epub 2006 Dec 6.


Metabolic gene variants and risk of non-Hodgkin's lymphoma.

De Roos AJ, Gold LS, Wang S, Hartge P, Cerhan JR, Cozen W, Yeager M, Chanock S, Rothman N, Severson RK.

Cancer Epidemiol Biomarkers Prev. 2006 Sep;15(9):1647-53.


Genetic variation in N-acetyltransferase 1 (NAT1) and 2 (NAT2) and risk of non-Hodgkin lymphoma.

Morton LM, Schenk M, Hein DW, Davis S, Zahm SH, Cozen W, Cerhan JR, Hartge P, Welch R, Chanock SJ, Rothman N, Wang SS.

Pharmacogenet Genomics. 2006 Aug;16(8):537-45.


SNP500Cancer: a public resource for sequence validation, assay development, and frequency analysis for genetic variation in candidate genes.

Packer BR, Yeager M, Burdett L, Welch R, Beerman M, Qi L, Sicotte H, Staats B, Acharya M, Crenshaw A, Eckert A, Puri V, Gerhard DS, Chanock SJ.

Nucleic Acids Res. 2006 Jan 1;34(Database issue):D617-21.


Polymorphisms and haplotypes in the cytochrome P450 17A1, prolactin, and catechol-O-methyltransferase genes and non-Hodgkin lymphoma risk.

Skibola CF, Bracci PM, Paynter RA, Forrest MS, Agana L, Woodage T, Guegler K, Smith MT, Holly EA.

Cancer Epidemiol Biomarkers Prev. 2005 Oct;14(10):2391-401.


Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001.

Morton LM, Wang SS, Devesa SS, Hartge P, Weisenburger DD, Linet MS.

Blood. 2006 Jan 1;107(1):265-76. Epub 2005 Sep 8.


20-year outcomes following conservative management of clinically localized prostate cancer.

Albertsen PC, Hanley JA, Fine J.

JAMA. 2005 May 4;293(17):2095-101.


Association of NAT and GST polymorphisms with non-Hodgkin's lymphoma: a population-based case-control study.

Chiu BC, Kolar C, Gapstur SM, Lawson T, Anderson JR, Weisenburger DD.

Br J Haematol. 2005 Mar;128(5):610-5.


Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells.

Dave SS, Wright G, Tan B, Rosenwald A, Gascoyne RD, Chan WC, Fisher RI, Braziel RM, Rimsza LM, Grogan TM, Miller TP, LeBlanc M, Greiner TC, Weisenburger DD, Lynch JC, Vose J, Armitage JO, Smeland EB, Kvaloy S, Holte H, Delabie J, Connors JM, Lansdorp PM, Ouyang Q, Lister TA, Davies AJ, Norton AJ, Muller-Hermelink HK, Ott G, Campo E, Montserrat E, Wilson WH, Jaffe ES, Simon R, Yang L, Powell J, Zhao H, Goldschmidt N, Chiorazzi M, Staudt LM.

N Engl J Med. 2004 Nov 18;351(21):2159-69.

Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk